Author

L. Denney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

L.-P. Ho· 2 shared A. Antanaviciute· 1 shared A. R. Cross· 1 shared C. Clelland· 1 shared C. de Andrea· 1 shared C. S. Hardman· 1 shared C. Vuppusetty· 1 shared E. Fraser· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

L.-P. Ho

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury

A. R. Cross, C. de Andrea, M. Villalba-Esparza, M. Landecho Acha, L. Cerundolo, P. Weeratunga, R. Etherington, L. Denney, G. Ogg, L.-P. Ho, I. Roberts, J. Hester, P. Klenerman, I. Melero, S. Sansom, F. Issa

The paper uses spatial transcriptomics to identify immune circuits in severe COVID-19 lung tissue, finding IFNγ response signatures linked to alveolar damage.

bioRxiv · Jun 21, 2021Immunology

Type-1 IFN primed monocytes in pathogenesis of idiopathic pulmonary fibrosis

L.-P. Ho, E. Fraser, L. Denney, K. Blirando, C. Vuppusetty, A. Antanaviciute, Y. Zheng, E. Repapi, V. Iotchkova, S. Taylor, N. Ashley, V. St Noble, R. Hoyles, R. Benamore, C. Clelland, , J. Rehwinkel

The paper identifies type-1 IFN-primed monocytes as key drivers of fibrosis in IPF, showing their increased levels, altered phenotype, and potential as therapeutic targets.

bioRxiv · Jan 16, 2020 · PreprintImmunology